The Children's Place says Amazon will launch its Gymboree brand on its website in July
(END) Dow Jones Newswires
May 19, 2022 07:05 ET (11:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.
|
|
|
|
|
(END) Dow Jones Newswires
May 19, 2022 07:05 ET (11:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2022. All rights reserved.